Vifor Pharma Group increased equity stake in ChemoCentryx from 6.6% to 21.2%, for $86m

Vifor Pharma Group acquired an additional 14.6% stake of ChemoCentryx, Inc. (NASDAQ: CCXI) from GlaxoSmithKline. As a result Vifor Pharma Group will hold a total of 21.2% of ChemoCentryx on completion of the transaction. The purchase price was approximately $86 million. “This investment is a logical step in strengthening our partnership with ChemoCentryx and towards realizing our vision of becoming global leader in nephrology,” said Stefan Schulze, Vifor Pharma Group President of the Executive Committee and COO.